Skip to main content
. 2025 Jun 25;64:43645. doi: 10.2340/1651-226X.2025.43645

Figure 3.

Figure 3

A schematic illustration of the mechanism of action of adjuvant treatment options in HR+/HER2- breast cancer after chemotherapy. Selective estrogen receptor degraders are shown as an example of potential future therapeutic options, but they are not indicated in the treatment of early breast cancer. CDK: cyclin-dependent kinase; GnRH: gonadotropin-releasing hormone. Figure created with bioRender.